The strategy addresses a central challenge in cancer immunotherapy. Many treatments can kill tumour cells, but cell death does not automatically produce effective antitumour immunity. For immune cells to recognize and attack cancer, dying tumour cells must release or display molecular signals that stimulate antigen-presenting cells. These signals, often described as damage-associated molecular patterns, can promote the uptake of tumour material by dendritic cells and help initiate T-cell responses. The researchers sought to design a form of cell death that would not simply eliminate tumour cells, but would also make their destruction immunologically productive.

The key component, aMP₍C16₎-CA₅₀, is a synthetic acid-responsive membranolytic peptide. Peptides of this class can disrupt lipid membranes by interacting with their surfaces and inserting into the bilayer, potentially forming defects or pores that compromise membrane integrity. What distinguishes this molecule is its hierarchical response to acidity. Tumour tissues commonly possess a mildly acidic extracellular environment, while lysosomes inside cells are substantially more acidic. The peptide was designed to respond to these changing pH conditions in stages, allowing its activity to be controlled by both location and time.

This sequence begins as the peptide encounters the acidic environment surrounding tumour cells and subsequently enters the cells. Once transported into lysosomes, where the pH is lower, the molecule becomes more strongly activated and damages lysosomal membranes. Lysosomal rupture releases enzymes and other contents into the cytoplasm, generating intense intracellular stress and activating inflammatory pathways. The plasma membrane then ruptures later, rather than simultaneously. According to the study, this delay is crucial: it gives the tumour cell time to develop an inflammatory transcriptional response before its final collapse and may improve the quality of the immune signals released during lysis.

The researchers describe this programmed process as immunogenic membranolytic cell death, or mLCD. Its defining feature is therefore not merely membrane destruction, but the spatiotemporal coordination of membrane damage. The order in which the lysosomal and plasma membranes fail can influence how a dying cell communicates with the immune system. Early lysosomal disruption may activate intracellular danger pathways, while delayed plasma-membrane rupture releases tumour-associated antigens and inflammatory mediators into the surrounding tissue. This combination could provide immune cells with both the warning signals and the tumour-specific material needed to mount a coordinated response.

Laboratory experiments indicated that aMP₍C16₎-CA₅₀ activated inflammatory gene-expression programs in tumour cells. These programs increased the ability of tumour-cell material to stimulate antigen presentation by dendritic cells. Antigen presentation is a critical bridge between innate and adaptive immunity: dendritic cells process proteins from damaged cells, load fragments onto major histocompatibility complex class I molecules and display them to T cells. When the displayed fragments originate from tumour cells, this interaction can help activate cytotoxic T lymphocytes capable of recognizing and killing cancer cells elsewhere in the body.

The findings also connect the peptide’s membrane-disrupting kinetics to the performance of immune checkpoint blockade. Checkpoint inhibitors, including therapies aimed at pathways such as PD-1, PD-L1 or CTLA-4, can restore T-cell activity, but they often work best when a tumour has already generated a strong immune response. By increasing antigen release and inflammatory signalling, the programmed mLCD approach may help convert immunologically quiet tumours into more responsive ones. In the reported experiments, aMP₍C16₎-CA₅₀ substantially enhanced the antitumour effects of immune checkpoint blockade, suggesting that the peptide could function as an immune-priming treatment rather than as a stand-alone cytotoxic agent.

The study further reports that systemic administration of the peptide was well tolerated in mice, an important consideration for any membrane-lytic therapy. Molecules that disrupt membranes can raise concerns about damage to healthy tissues, red blood cells or vital organs. The researchers’ pH-dependent design is intended to concentrate activity in acidic tumour environments and intracellular lysosomes, potentially limiting unwanted effects in normal tissues. However, the safety results remain preclinical. The distribution, metabolism, immune effects and toxicity of the peptide will need to be examined in more advanced animal studies before its relevance to human treatment can be determined.

The work illustrates a broader shift in cancer-drug design: instead of treating cell death as a single endpoint, researchers are attempting to program how, where and when a tumour cell dies. By manipulating membrane biology with a synthetic peptide, the team created a death process that links physical destruction to inflammatory gene activation and adaptive immune stimulation. If the concept can be translated safely beyond mice, pH-responsive membranolytic peptides could become a versatile platform for improving immunotherapy, particularly in tumours that currently resist checkpoint inhibitors. For now, the study provides a striking example of how precisely timed cellular damage can transform tumour-cell death into an active signal for the immune system.

Subject of Research:
A pH-responsive synthetic membranolytic peptide designed to induce immunogenic membranolytic cell death in tumour cells and enhance immune checkpoint blockade therapy.

Article Title:
Membranolytic peptide programs immunogenic cell death for cancer therapy

Article References:
Yuan, Y., Liang, L., Li, J. et al. “Membranolytic peptide programs immunogenic cell death for cancer therapy.” Nature (2026). https://doi.org/10.1038/s41586-026-10899-5

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41586-026-10899-5

Keywords:
Immunogenic cell death, membranolytic peptide, cancer immunotherapy, pH-responsive therapy, lysosomal membrane rupture, plasma membrane rupture, dendritic cells, T-cell activation, immune checkpoint blockade, tumour microenvironment

The immune system’s ability to recognize and eliminate cancer cells hinges on effective antigen presentation, a process primarily mediated by the human leukocyte antigen class I (HLA-I) complex. Tumor antigens are processed and presented on HLA-I molecules on the cancer cell surface, flagging aberrant cells for destruction by CD8+ cytotoxic T lymphocytes. Paradoxically, BCC cells suppress the expression of HLA-I, effectively cloaking themselves in immunological invisibility. This suppression results from a sophisticated epigenomic mechanism connected to the tumor’s cell of origin and its intrinsic stemness programs.

Dr. Demehri’s team meticulously compared BCC samples to cutaneous squamous cell carcinomas (SCCs), which exhibit higher responsiveness to immune checkpoint inhibitors. Through single-cell RNA sequencing and histological analyses, they demonstrated that BCCs harbor an "immune-excluded" microenvironment, characterized by minimal infiltration of CD4+ and CD8+ T cells within tumor foci. This contrasts sharply with SCCs, where immune cells readily penetrate the tumor stroma. The immune exclusion observed in BCC correlates tightly with the downregulation of antigen presentation machinery (APM), evident even at early disease stages, suggesting an inherent, developmental basis for immune evasion.

Central to this suppression is the transcription factor Foxc1, which is normally involved in maintaining quiescence of hair follicle stem cells — the presumptive cell of origin for BCC. Foxc1 directly represses genes encoding key components of the APM, including HLA-I and interferon regulatory factor 1 (IRF1), through epigenomic modifications that silence their expression. This pharmacologically reversible epigenetic repression provides a molecular explanation for why BCCs, despite their heavy mutational load, remain largely undetected and refractory to immune attack.

The clinical implications of these discoveries are profound. Dr. Demehri’s research shows that topical application of entinostat, a histone deacetylase inhibitor, can epigenetically reverse APM suppression in BCC cells in vivo. When used in combination with imiquimod, a topical immune response modifier approved for skin cancers, entinostat significantly enhances antigen presentation and stimulates immune cell infiltration, producing a synergistic antitumor effect. This dual-regimen effectively overcomes the immune exclusion barrier, transforming BCC from an immunologically "cold" tumor into one more amenable to immune-mediated clearance.

Such findings challenge the existing paradigm that high tumor mutational burden necessarily predicts immunotherapy success. Instead, they emphasize the pivotal role of a cancer’s cellular and epigenetic context, particularly the intrinsic stemness programs inherited from their cell of origin, in dictating immunogenicity. By targeting these epigenomic regulators, it may be possible to sensitize otherwise resistant tumors to immune-based treatments, broadening the therapeutic horizon beyond BCC.

Beyond immediate treatment strategies, this work raises critical questions about how tissue-specific stemness pathways modulate tumor-immune interactions more broadly. Could similar epigenetic constraints on antigen presentation operate in other cancers arising from quiescent stem cell populations? If so, unraveling these intrinsic immunosuppressive mechanisms may unlock new generalizable approaches to cancer immunotherapy.

Furthermore, these insights offer hope for organ transplant recipients and immunosuppressed patients, who are disproportionately susceptible to SCC yet relatively spared from BCC development. This differential risk underscores the clinical relevance of BCC’s low immunogenicity and may inform personalized surveillance and therapeutic strategies for high-risk populations.

In essence, this study elegantly combines molecular immunology, epigenomics, and clinical oncology to redefine our understanding of tumor immune evasion. The identification of Foxc1 as a master regulator of antigen presentation heralds a new chapter in skin cancer research and immunotherapy, anchored in the biology of the tumor’s origin rather than mutation burden alone.

Looking forward, Dr. Demehri and colleagues advocate for clinical trials testing the efficacy and safety of entinostat-primed immunotherapy in patients with BCC. Such trials could validate this novel combination as a frontline or adjunct treatment, potentially improving outcomes for thousands of patients afflicted with this common yet challenging cancer.

This research exemplifies the power of combining cutting-edge single-cell technologies with translational oncology to unravel the complex interplay between cancer cell states and immune recognition. As the field of cancer immunotherapy continues to evolve, studies like this underscore the importance of considering tumor cell origin and epigenetic regulation when designing effective treatments.

In conclusion, the elucidation of epigenomic mechanisms governing stemness and immune suppression opens promising avenues not only for the treatment of basal cell carcinoma but also for a broader understanding of cancer immunobiology. By leveraging these insights, the oncology community stands poised to overcome longstanding barriers in combating immune-resistant tumors, heralding a new era of precision medicine and immunotherapy.

Subject of Research: Cells

Article Title: Epigenomic regulation of stemness contributes to the low immunogenicity of the most mutated human cancer

News Publication Date: 17-Apr-2025

Web References:

• https://www.cell.com/cell-reports/fulltext/S2211-1247(25)00332-8
• http://dx.doi.org/10.1016/j.celrep.2025.115561

Image Credits: Shawn Demehri, Massachusetts General Hospital

Keywords: Skin cells, Immunogenicity, Combination therapies, Cancer immunotherapy